Company: CERO
Filing Date: 2025-07-14
Form Type: 8-K
Source: 0001213900-25-063475
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-14
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry into a Material Definitive Agreement.

As previously disclosed, CERo Therapeutics Holdings,
Inc., a Delaware corporation (the “ Company”) and an institutional investor (the “ Investor”) entered into a common
stock purchase agreement on each of February 14, 2024 (the “ February Purchase Agreement”) and November 8, 2024 (the “ November
Purchase Agreement” and, collectively, the “ Prior Purchase Agreements”), pursuant to which, upon the terms and subject
to the conditions and limitations set forth in such Prior Purchase Agreements, the Company may issue and sell to the Investor up to an
aggregate of $25.0 million of the Company’s outstanding common stock, par value $0.0001 per share (the “ Common Stock”).
As of June 30, 2025, the Company has issued and sold (i) 11,689 shares of Common Stock for aggregate proceeds of approximately $4.4 million
pursuant to the February Purchase Agreement, and (ii) 100,584 shares of Common Stock for aggregate proceeds of approximately $3.1 million
pursuant to the November Purchase Agreement. Accordingly, in order to enable the Company to issue and sell and the Investor to purchase
from the Company, an aggregate of $25,000,000 of the Company’s outstanding shares of Common Stock, the Company and the Investor
have entered into the new Purchase Agreement described below.

On July 11, 2025, the Company entered into a purchase
agreement (the “ Purchase Agreement”) with the Investor, pursuant to which the Company may issue and sell to the Investor,
from time to time as provided in the Purchase Agreement, and the Investor shall purchase from the Company up to $17,490,897 of the Company’s
outstanding shares of Common Stock, minus any additional proceeds received from the sale of shares of Common Stock pursuant to the November
Purchase Agreement after June 30, 2025 and subject to the satisfaction of the conditions in the Purchase Agreement. Capitalized terms
not otherwise defined shall have the meaning ascribed to them in the Purchase Agreement.

As the Purchase Agreement constitutes a continuation
of the equity line program commenced under the Prior Purchase Agreement, the Commitment Shares issued to the Investor pursuant to the
Prior Purchase Agreement shall satisfy in full the Company’s obligation to deliver any additional shares of Common Stock to the
Investor as consideration for entering into the Purchase Agreement.

At any time from and